Center of Excellence for Pulmonary Hypertension
The aim of the center is the accurate modern examination and treatment of patients with rare and extremely severe pathology - PAH and chronic thrombotic embolic pulmonary hypertension (CTEPH) - as well as the further care of these patients. We run screening programs for patients with systemic sclerosis of preparing for liver transplantation.
Read more about COVID-19 and pulmonary hypertension.
The patient monitoring system of the center has more than 500 persons. More than 140 patients with PAH and CTEPH are currently being monitored and treated. All of them are given specific treatment for PAH. Also, pulmonary endarterectomy and/or balloon pulmonary angioplasty may be performed in patients with CTEPH.
Biochemical, genetic research, advanced disease detection methods, radiological diagnostics are applied and performed at our center. CEPH is a member of the European Reference Network on Rare Respiratory Diseases (ERN-LUNG) (more information: https://ern-lung.eu/).
The center has developed a unique monitoring system that collects data on newly diagnosed cases, tracks the course of the disease, and evaluates the effectiveness of treatment. The collected data is analyzed and constantly updated.
CEPH prioritizes the development of clinical, biomedical research that encourage medical innovation. Therefore, patients are the first to receive a new advanced treatment for PAH. The center organizes and develops epidemiological studies of treatment outcomes and continuously improves treatment protocols according to the principles of evidence-based medicine. Our physicians organize local and international conferences and regularly participate in international conferences.
the-center-of-excellence-for-pulmonary-hypertension-scientific-publications.pdf
